Purple Biotech’s Phase 2 trial of CM24 in metastatic PDAC patients showed improved survival rates, biomarker responses, and disease control outcomes.
Why Is Purple Biotech Stock Trading Higher On Monday?
Where Today's News Shapes Tomorrow
March 10, 2026
Headlines
